Oral absorption of the somatostatin analogue SMS 201–995: Theoretical and practical implications
- 1 February 1987
- journal article
- research article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 72 (2) , 255-257
- https://doi.org/10.1042/cs0720255
Abstract
1. Oral administration of SMS 201-995 (SMS), a subcutaneously injectable somatostatin analogue, was investigated in five healthy volunteers, who drank 2 mg of SMS with 75 g of glucose. 2. Mean maximal plasma SMS concentrations after the 2 mg oral dose were comparable with those after subcutaneous injection of 50 .mu.g, although the peak was delayed (90 vs 15 min). 3. Biological activity of absorbed SMS was shown by significant and lasting suppression of plasma insulin concentrations, resulting in significant hyperglycaemia at 90 and 120 min compared with the control study. 4. The feasibility of oral administration of SMS may extend its use in the treatment of acromegaly and gut endocrine tumours. Other peptide hormone analogues, structurally ''protected'' against enzymatic degradation, may also be active orally and thus be useful therapeutically.This publication has 6 references indexed in Scilit:
- Long-Term Treatment of Acromegaly with the Somatostatin Analogue SMS 201–995New England Journal of Medicine, 1985
- Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.Gut, 1985
- Use of a long acting somatostatin analogue in controlling life threatening ileostomy diarrhoea.BMJ, 1984
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- The Effect of Somatostatin Analogs on Secretion of Growth, Pancreatic, and Gastrointestinal Hormones in ManJournal of Clinical Endocrinology & Metabolism, 1981
- Metabolic Clearance and Plasma Half-Disappearance Time of Exogenous Somatostatin in Man*Journal of Clinical Endocrinology & Metabolism, 1979